EXIT-CVD Exit-cvd
- Coordinator
- Academisch Ziekenhuis Groningen, Netherlands
- Runs
- 1 April 2026 to 31 March 2031
- Status
- Running
- EU funding
- €15.2m
- Total cost
- €27.7m
- Partners
- 43 organisations in 17 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101253160
What the project is doing
In the project's own words, from its summary on CORDIS.
EXIT-CVD aims to fundamentally transform cardiovascular disease (CVD) management by enabling early, personalized, and equitable interventions across the CVD continuum. Recognizing CVD as a dynamic progression, from risk factors to heart failure and premature death, EXIT-CVD identifies and operationalizes strategic ""exit points"" where disease trajectories can be disrupted. Through a multidisciplinary, public-private partnership involving academia, Medtech, pharma, SMEs, and patient organizations, the project will integrate state-of-the-art diagnostics (e.g., photon-counting CT, AI-enhanced wearables), digital monitoring, regenerative therapies, and advanced imaging-guided interventions.
Innovations are embedded in a digitally enabled, FAIR-compliant data platform aligned with the European Health Data Space (EHDS), ensuring real-world scalability and regulatory readiness. EXIT-CVD rigorously applies implementation science through the frameworks RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) which evaluates interventions along five core dimensions relevant to health systems uptake, and PROCTOR (Implementation Outcomes Framework) which focuses on concrete metrics such as acceptability, feasibility, fidelity, and cost.
Additionally, EXIT-CVD adopts an equity-by-design approach to overcome persistent health disparities. Clinical studies target early detection (e.g., wearable blood pressure and AI-Electrocardiogram monitoring), intermediate stratification (e.g., imaging-guided Percutaneous Coronary Intervention (PCI) with Photon-Counting Computed Tomography (PCCT)), and late-stage recovery (e.g., engineered heart muscle transplantation and minimally invasive cardiac surgery supported by mechanical circulatory devices).
By co-creating with patients and systematically addressing socioeconomic, gender, and digital access gaps, EXIT-CVD envisions a future where heart disease is not a terminal continuum but a preventable and reversible condition. This project will deliver validated, sustainable, and equitable innovations, positioning Europe at the forefront of cardiovascular health transformation.""
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Coordinator |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| Circle Cardiovascular Imaging Inc. | Calgary | Canada | Participant |
| Bgp Products Operations GmbH | Steinhausen | Switzerland | Participant |
| Ente Ospedaliero Cantonale | Bellinzona | Switzerland | Participant |
| Abiomed Europe GmbH | Aachen | Germany | Participant |
| Klinikum Der Universitaet Zu Koeln | Koeln | Germany | Participant |
| Philips GmbH | Hamburg | Germany | Participant |
| Repairon GmbH | Gottingen | Germany | Participant |
| Sanofi-Aventis Deutschland GmbH | Frankfurt Am Main | Germany | Participant |
| Siemens Healthineers AG | Forchheim | Germany | Participant |
| Zoll Cms GmbH | Koln | Germany | Participant |
| Bridg Ou | Tallin | Estonia | Participant |
| Fundacio De Gestio Sanitaria De L'hospital De La Santa Creu I Sant Pau | Barcelona | Spain | Participant |
| Medtronic Iberica SA | Madrid | Spain | Participant |
| Huawei Technologies Oy (finland) Co Ltd | Helsinki | Finland | Participant |
| Varsinais-Suomen Hyvinvointialue | Turku | Finland | Participant |
| Societe Europeenne De Cardiologie | Biot | France | Participant |
| Megi Health d.o.o. | Zagreb | Croatia | Participant |
| Centro Cardiologico Monzino | Milano | Italy | Participant |
| Politecnico Di Milano | Milano | Italy | Participant |
| Universita Degli Studi Di Pavia | Pavia | Italy | Participant |
| Corbotics B.V. | Delft | Netherlands | Participant |
| Cordys Analytics B.V. | Utrecht | Netherlands | Participant |
| Iqvia Solutions B.v. | Amsterdam | Netherlands | Participant |
| Johnson & Johnson Medical B.v. | Amersfoort | Netherlands | Third party |
| Novartis Pharma B.V. | Amsterdam | Netherlands | Participant |
| Philips Electronics Nederland BV | Eindhoven | Netherlands | Participant |
| Philips Nederland BV | Eindhoven | Netherlands | Participant |
| Stichting VrouwenHart | Leidschendam | Netherlands | Participant |
| Technische Universiteit Eindhoven | Eindhoven | Netherlands | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego - Panstwowy Instytut Badawczy | Warszawa | Poland | Participant |
| Cardio Med SRL | Targu Mures | Romania | Participant |
| Astrazeneca AB | Sodertaelje | Sweden | Participant |
| Xvivo Perfusion Aktiebolag | Goteborg | Sweden | Participant |
| Huawei Telekomünikasyon Dis Ticaret Limited Sirketi | İstanbul | Türkiye | Participant |
| Cogstack Limited | Hadlow | United Kingdom | Participant |
| King's College London | London | United Kingdom | Participant |
| London School of Economics and Political Science | London | United Kingdom | Participant |
| Onsentia Limited | Hadlow Kent | United Kingdom | Participant |
| Ge Precision Healthcare Llc | Wilmington | United States | Participant |
| Heartbeam Inc | Santa Clara | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI